StemCells (STEM) Bullish Stance Reiterated at Maxim Group on Positive Spine Paralysis Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
StemCells (STEM) Provided Data on Phase I/II Trial in Spinal Cord Injury
May 19, 2014 8:10 AM EDTStemCells, Inc. (Nasdaq: STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in two patients have now been observed in two additional patients.
The presentation included the first data on AIS B subjects to be transplanted in the Phase I/II chronic... More
StemCells (STEM) Posts Q1 Results and Data Is Coming, Maxim Group Says
May 15, 2014 7:39 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $2.50 price target on StemCells (NASDAQ: STEM) following first quarter results and an overall update on the current clinical programs with a focus on PI/II spine and AMD trials.
The analyst... More
